F-1/A: Cuprina Holdings Eyes Nasdaq Listing with $[] Million IPO, Resale Offering

Cuprina Holdings (Cayman) Limited files for an initial public offering of 2,500,000 Class A Ordinary Shares, alongside a resale offering of 1,500,000 Class A Ordinary Shares by existing shareholders, seeking to list on the Nasdaq Capital Market under the ticker CUPR.

Summary

• Cuprina Holdings (Cayman) Limited, a Singapore-based biomedical company, is planning an initial public offering (IPO) of 2,500,000 Class A Ordinary Shares.
• The company has applied to list its Class A Ordinary Shares on the Nasdaq Capital Market under the symbol CUPR.
• The IPO's success is contingent upon Nasdaq's approval of the listing application.
• Concurrently, existing shareholders, Ms. Dorea Quek En Qi and Mr. Bryan Teo Ying Jie, are offering 1,500,000 Class A Ordinary Shares in a resale offering.
• Cuprina will not receive any proceeds from the resale offering.
• The company's Class A Ordinary Shares and Class B Ordinary Shares have different voting rights, with Class B shares carrying 10 votes each and Class A shares carrying one vote each.
• Cuprina Holdings will remain a controlled company post-IPO, as Cuprina Holding Pte. Ltd. will hold more than 50% of the voting power.
• The company is an emerging growth company and a foreign private issuer, entitling it to reduced reporting requirements.
• Cuprina's revenue for 2023 was S$100,773 (US$76,424), with a net loss of S$1,119,555 (US$849,048).

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is pursuing growth opportunities and has innovative products, it also faces financial challenges, including a history of losses and concerns about its ability to continue as a going concern.

Positives

• The company has strategic plans to expand sales and establish physical operations in Southeast Asia, the Middle East, and mainland China in the second half of 2024 and 2025.
• The company's commitment to quality is demonstrated by its attainment of ISO 13485:2016 standards for its manufacturing facility in Singapore in 2020.
• The company is working towards obtaining compliance with 21 CFR Part 820 to secure FDA 510(k) clearance for its chronic wound care products.

Negatives

• The company has incurred losses since its formation and expects to continue to incur losses for the foreseeable future.
• The company recorded net current liabilities as of December 31, 2021, 2022 and 2023, and such positions may continue after this offering.
• The company had net operating cash outflows for the years ended December 31, 2021, 2022 and 2023.
• The company's independent registered public accounting firm expressed substantial doubt regarding its ability to continue as a going concern.

Risks

• An active trading market for the company's Class A Ordinary Shares may not be established or, if established, may not continue and the trading price for the Class A Ordinary Shares may fluctuate significantly.
• The company may not maintain the listing of its Class A Ordinary Shares on the Nasdaq which could limit investors ability to make transactions in Class A Ordinary Shares and subject the company to additional trading restrictions.
• The trading price of the company's Class A Ordinary Shares may be volatile, which could result in substantial losses to investors.
• The company's corporate actions are significantly influenced by its directors, officers and principal shareholders, who have the ability to exert significant influence over important corporate matters that require approval of shareholders while their interests may differ from those of the other shareholders.
• The dual-class structure of the company's ordinary shares may adversely affect the trading market for its Class A Ordinary Shares.
• The sale or availability for sale of substantial amounts of the company's Class A Ordinary Shares could adversely affect their market price.

Future Outlook

The company plans to expand into new geographic markets, continue to expand its product portfolio through development and innovation, strengthen brand awareness, and attract, cultivate and retain a talented and professional workforce.

Industry Context

The company operates in the biomedical and biotechnology industry, focusing on chronic wound care and cosmeceuticals, which are experiencing growth due to an aging population and increasing prevalence of comorbidities.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or benchmarks.
• However, it mentions Fortune Business Insights' data on the global chronic wound care market size, indicating a market size of US$11.6 billion in 2021, expected to reach US$19.5 billion in 2029, representing a CAGR of 6.7%.

Related Party Transactions

• The document discloses amounts due from and to related parties, including shareholders and related companies, for working capital purposes.
• It also mentions management fees received from a related party and interest expense on loans from an ultimate beneficial owner.

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of new shares.
• Employees: Potential for increased job opportunities due to expansion plans.
• Customers: Access to innovative products for chronic wound care and cosmeceuticals.
• Suppliers: Potential for increased business due to increased production.

Next Steps

• Obtain Nasdaq approval for listing.
• Complete the IPO and resale offering.
• Expand into new geographic markets.
• Continue research and development activities.
• Strengthen brand awareness.

Key Dates

Keywords

IPO, initial public offering, Cuprina Holdings, Class A Ordinary Shares, Nasdaq, resale offering, biomedical, biotechnology, wound care, MEDIFLY, maggot debridement therapy, cosmeceuticals